Table 1.
IPVD Therapy Versus non-IPVD Therapy COVID-19 ICU Patients.
| IPVD (n = 59) | No IPVD (n = 249) | p-value | |
|---|---|---|---|
| Age (years) | 60 (54-66) | 60 (47-71) | 0.753 |
| Gender (n (%)) | |||
| Male | 37 (62.7%) | 164 (65.9%) | 0.648 |
| Female | 22 (37.3%) | 85 (34.1%) | |
| BMI (kg/m2) | 31.1 (27.1-35.9) | 30.5 (26-34.8) | 0.274 |
| Ethnicity (n (%)) | |||
| White | 41 (69.5%) | 190 (76.3%) | 0.609 |
| Asian | 12 (20.3%) | 38 (15.3%) | |
| Black | 4 (6.8%) | 11 (4.4%) | |
| Mixed | 2 (3.4%) | 6 (2.4%) | |
| Unknown | - | 4 (1.6%) | |
| Comorbidities (n (%)) | |||
| T1DM | 0 (0%) | 7 (2.8%) | 0.354 |
| T2DM | 17 (28.8%) | 64 (25.7%) | 0.626 |
| COPD | 3 (5.1%) | 15 (6.0%) | 1.000 |
| Hypertension | 28 (47.5%) | 101 (40.6%) | 0.334 |
| Ischaemic heart disease | 3 (5.1%) | 34 (13.7%) | 0.069 |
| CKD | 5 (8.5%) | 17 (6.8%) | 0.585 |
| Illness severity scores | |||
| APACHE-II | 17 (12-23) | 13 (10-20) | 0.028* |
| Admission oxygenation indices | |||
| FiO2 | 0.7 (0.55-0.8) | 0.6 (0.5-0.7) | 0.001* |
| PaO2 (kPa) | 9.41 (8.55-11.10) | 9.96 (8.50-9.96) | 0.144 |
| PF ratio (kPa) | 14.37 (11.64-18.5) | 16.37 (13.70-21.44) | 0.002* |
| Admission bloods | |||
| Lactate (mmol/L) | 1.2 (1.0-1.6) | 1.0 (0.8-1.4) | 0.013* |
| WCC (109/L) | 8.2 (6.0-11.0) | 8.5 (6.0-12.0) | 0.379 |
| Neutrophils (109/L) | 7.2 (5.2-9.43) | 7.6 (5.1-10.4) | 0.540 |
| Lymphocytes (109/L) | 0.6 (0.5-0.8) | 0.8 (0.5-1.1) | 0.004* |
| Ferritin (μg/L) | 774 (534-1237) | 683 (376-1281) | 0.547 |
| Troponin (ng/L) | 15 (8-43) | 13 (7-44) | 0.698 |
| LDH (U/L) | 1022 (829-1400) | 874 (687-1211) | 0.005* |
| D-Dimer (μg/L) | 583 (283-1141) | 553 (283-1176) | 0.888 |
| Creatinine Kinase (U/L) | 148 (54-381) | 131 (68-342) | 0.997 |
| Treatments (n (%)) | |||
| Transfer for ECMO | 1 (1.7%) | 4 (1.6%) | 1.000 |
| Renal replacement therapy | 15 (25.4%) | 34 (13.7%) | 0.026* |
| Survival (n (%)) | |||
| ICU survival | 33 (55.9%) | 204 (81.9%) | <0.001* |
| Hospital survival | 31 (52.5%) | 199 (79.9%) | <0.001* |